交易行情显示，12月12日，*ST沪科收跌0.26%，收于3.81元/股，总市值12.53亿元。 北京商报讯（记者 马换换 李佳雪）12月12日晚间，*ST沪科（600608）披露公告称，公司于当日收到 证监会下发的《立案告知书》，因涉嫌信息披露违法违规，证监会决定对公司立案。 *ST沪科表示，目前，公司各项生产经营活动正常有序开展，上述事项不会对公司经营和管理造成重大 影响。 ...

Group 1 - *ST Hu Ke received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws, leading to a formal case being opened against the company [2] - The company stated that its production and operational activities are currently normal and that the investigation will not have a significant impact on its management and operations [4] - The main business of *ST Hu Ke involves the trade of agricultural and chemical products, classified under "F51 Wholesale Industry" according to the CSRC [4] Group 2 - As of December 12, *ST Hu Ke's stock price was 3.81 yuan per share, with a total market capitalization of 1.253 billion yuan [5] - Humanwell Healthcare announced that it received an administrative penalty notice from the CSRC for failing to disclose non-operating fund occupation and related transactions in its annual reports, which contained significant omissions and false records [5] - Humanwell Healthcare's stock will be subject to risk warnings starting December 16, with a daily price fluctuation limit of 5% after being placed on the risk warning board [6] Group 3 - Humanwell Healthcare, established in 1993, is a leading pharmaceutical company in Hubei Province, with a strong presence in various therapeutic areas and a comprehensive pharmaceutical value chain [8] - As of December 12, Humanwell Healthcare's stock price was 18.15 yuan per share, with a total market capitalization of 29.625 billion yuan [9]

Group 1 - *ST Hu Ke announced on December 12, 2025, that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to suspected violations of information disclosure laws [1][3] - The company stated that its production and operational activities are currently normal and that the investigation will not have a significant impact on its management [3] - The main business of *ST Hu Ke focuses on the trade of agricultural and chemical products, classified under "F51 Wholesale Industry" according to the CSRC [3] Group 2 - For the third quarter, *ST Hu Ke reported a revenue of 1.04 million yuan, a year-on-year decrease of 56.95%, with a net profit attributable to shareholders of 1.0271 million yuan [4] - As of December 12, 2025, *ST Hu Ke's stock price was 3.81 yuan per share, with a total market capitalization of 1.253 billion yuan [4] Group 3 - On the same day, Renfu Pharmaceutical announced it received a notice of administrative penalty from the CSRC for failing to disclose non-operating fund occupation and significant omissions in its annual reports for 2020 and 2022 [7] - Renfu Pharmaceutical's stock will be subject to risk warnings starting December 16, 2025, with a trading limit of 5% on price fluctuations [7][9] - The company, established in 1993, is a leading pharmaceutical enterprise in Hubei Province, focusing on a full industrial chain from intermediates to drug formulations [9] Group 4 - As of December 12, 2025, Renfu Pharmaceutical's stock price was 18.15 yuan per share, with a total market capitalization of 29.625 billion yuan [9]

Group 1 - Moer Thread plans to use up to 7.5 billion yuan of idle raised funds for cash management, with a usage period of 12 months [1] - O-film plans to purchase 8.46% equity of its subsidiary Anhui Che Lian for a total of 3.64 billion yuan, increasing its ownership from 78.54% to 87% [2] - ST Lian Shi applies to revoke the delisting risk warning as its restructuring plan has been completed [3] Group 2 - Weirli signs a strategic cooperation framework agreement with Primech Holdings to build an industrial robot cooperation platform [4] - Race Intelligent plans to raise no more than 1.144 billion yuan through a private placement for core components of intelligent equipment [5] - Renfu Pharmaceutical's stock will be subject to other risk warnings and will be suspended for one day starting December 15 [6] Group 3 - Yongding Co. clarifies that its subsidiary Dongbu Superconductor does not directly manufacture controllable nuclear fusion devices [7] - Rongbai Technology plans to acquire part of Guizhou Xinren's equity and increase its capital to achieve control [9] - ST Hu Ke is under investigation by the Securities Regulatory Commission for suspected information disclosure violations [10] Group 4 - Yunnan Ge Industry plans to establish a subsidiary focused on organic germanium-related products [11] - Greenme intends to acquire 16.38% equity of Henan Recycling Group for 400 million yuan [12] - Jiangzhong Pharmaceutical plans to change its name to China Resources Jiangzhong Pharmaceutical [13] Group 5 - Jiangsu Guoxin's subsidiary Ma Zhou Power has completed the trial operation of a 1,000 MW coal-fired power generation unit [16] - Longsheng Technology plans to invest in a center for embodied intelligent robots [18] - Guangzhou Development has received approval for the registration of 8 billion yuan medium-term notes and 6 billion yuan short-term financing notes [19] Group 6 - China Merchants Port reported a container throughput of 17.248 million TEUs in November, a year-on-year increase of 6.4% [20] - Tianma Technology reported a total eel output of approximately 11,415.87 tons from January to November [21] Group 7 - Xilong Science plans to reduce its stake by up to 1% [22] - Xicet Testing's actual controller plans to transfer 5% of the company's shares [23] - Oppein Home's actual controller plans to increase its stake by 50 million to 100 million yuan [24] Group 8 - Maide Medical plans to repurchase shares worth 20 million to 40 million yuan [25] - Baicheng Pharmaceutical's major shareholder increased its stake by 0.85% [26] - Mengbaihe's major shareholder plans to reduce its stake by up to 1% [27] Group 9 - Xian Dao Ji Dian's shareholder has reduced its stake by 1.70% [28] - Yaxiang Integration's shareholder reduced its stake by 41,400 shares [29] - Zhiwei Intelligent's actual controller has reduced its stake, bringing the total holding to 69% [30] Group 10 - Jincheng Co.'s actual controller plans to reduce its stake by up to 0.97% [31] - Jianghua Micro's chairman has reduced his stake by 1.09% [32] - COSCO Shipping Energy signed a shipbuilding contract worth 7.882 billion yuan [33] Group 11 - Dayu Water Saving's subsidiary is expected to win two high-standard farmland construction projects [34] - Guorui Technology's subsidiary is a candidate for the GXLF project [36] - ST Zhisheng has won a smart city governance project worth 104 million yuan [37]

Core Viewpoint - *ST沪科 is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, which may impact its operations and market perception [1][3]. Company Operations - The company reports that its production and business activities are currently operating normally and that it will cooperate with the regulatory investigation [3]. - *ST沪科, officially known as Shanghai Broadband Technology Co., Ltd., primarily engages in the trade of agricultural and chemical products, focusing on fresh-cut flowers and liquor grains in agriculture, and titanium dioxide in chemicals [3]. Financial Performance - The company's revenue has been declining significantly, with reported revenues of 367 million yuan in 2022, 149 million yuan in 2023, and a projected 17 million yuan in 2024, marking an 88.42% year-on-year decline for 2024 [3]. - For the first half of 2025, *ST沪科's revenue further decreased by 65% to approximately 4.4 million yuan, attributed to adjustments in business structure and declines in its chemical product lines [3][4]. - Key financial metrics for the first half of 2025 include a total profit of -442,431.75 yuan, a net profit attributable to shareholders of 34,921.86 yuan, and a net cash flow from operating activities of 26.26 million yuan, showing a significant decline compared to the previous year [4]. Stock and Market Performance - The company's stock has been under pressure, with a nearly 20% decline in share price over the past month, resulting in a market capitalization of approximately 1.3 billion yuan as of December 12 [6]. - Due to negative financial results, *ST沪科's stock has been placed under a delisting risk warning, as it failed to meet the revenue threshold of 300 million yuan [4]. Historical Issues - The company faces issues related to non-operating fund occupation, with a balance of 349 million yuan owed by its former controlling shareholder, significantly exceeding its net assets [5]. - In November 2023, *ST沪科 announced plans to transfer all debts related to historical issues with Nanjing Siweit Group, although the success of this plan remains uncertain [5]. Management Changes - There has been frequent turnover in the company's management, with the resignation of the board secretary and financial officer, who had only served for about a year due to personal health reasons [6].

Group 1 - *ST HuKe announced on December 12, 2025, that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to suspected violations of information disclosure laws [2] - The company stated that its production and operational activities are currently normal and that the investigation will not have a significant impact on its management [4] - For the first half of 2025, *ST HuKe's main business included agricultural products, particularly fresh-cut flowers and liquor grains, and chemical products, mainly titanium dioxide [4] Group 2 - In the third quarter, *ST HuKe reported revenue of 1.04 million yuan, a year-on-year decrease of 56.95%, with a net profit attributable to shareholders of 1.0271 million yuan [5] - As of December 12, 2025, *ST HuKe's stock price was 3.81 yuan per share, with a total market capitalization of 1.253 billion yuan [6] Group 3 - Renfu Pharmaceutical announced on December 12, 2025, that it received a notice of administrative penalty from the CSRC for failing to disclose non-operating fund occupation and significant omissions in its annual reports for 2020 and 2022 [8] - The company will face risk warnings on its stock starting December 16, 2025, with a daily price limit of 5% after the warning is implemented [8] - Renfu Pharmaceutical, established in 1993, is a leading pharmaceutical company in Hubei, focusing on a full industrial chain from intermediates to drug formulations, and has a global presence with over 80 products exported to more than 70 countries [10] Group 4 - As of December 12, 2025, Renfu Pharmaceutical's stock price was 18.15 yuan per share, with a total market capitalization of 29.625 billion yuan [11]

*ST沪科（600608）(600608.SH)发布公告，公司于2025年12月12日收到中国证券监督管理委员会下发的 《立案告知书》(编号:证监立案字0032025030号)。因涉嫌信息披露违法违规，根据《中华人民共和国证 券法》《中华人民共和国行政处罚法》等法律法规，中国证券监督管理委员会决定对公司立案。 ...

Core Viewpoint - The company *ST Huike (600608.SH) has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws [1] Group 1 - The company was issued a "Notice of Case Filing" (No. 0032025030) by the CSRC on December 12, 2025 [1] - The investigation is based on allegations of illegal information disclosure [1] - The CSRC's decision to file a case is in accordance with the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China [1]

人民财讯12月12日电，*ST沪科（600608）12月12日公告，公司于2025年12月12日收到证监会下发的立 案告知书。因涉嫌信息披露违法违规，根据相关法律法规，证监会决定对公司立案。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海宽频科技股份有限公司 关于收到中国证券监督管理委员会立案告知书的 公告 证券代码：600608 证券简称：*ST 沪科 公告编号：临 2025-064 上海宽频科技股份有限公司（以下简称"公司"）于2025年12月12日收到中国 证券监督管理委员会下发的《立案告知书》(编号:证监立案字0032025030号)。因 涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政 处罚法》等法律法规，中国证券监督管理委员会决定对公司立案。 目前，公司各项生产经营活动正常有序开展，上述事项不会对公司经营和管 理造成重大影响。公司将积极配合中国证券监督管理委员会立案调查工作，并按 照有关法律法规等规定和要求,及时做好信息披露工作。敬请广大投资者注意投 资风险。 特此公告。 上海宽频科技股份有限公司董事会 2025 年 12 月 13 日 ...